A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder

Archives of General Psychiatry

Volumn 57, Issue 5, 2000, Pages 481-489

  Bowden, Charles L ^a   Calabrese, Joseph R ^b   McElroy, Susan L ^c   Gyulai, Laszlo ^d   Wassef, Adel ^e   Petty, Frederick ^g   Pope Jr , Harrison G ^h,i   Chou, James C Y ^j   Keck Jr , Paul E ^c   Rhodes, Linda J ^a   Swann, Alan C ^f   Hirschfeld, Robert M A ^k   Wozniak, Patricia J ^l  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF TEXAS   (United States)

^f Medical School   (United States)

^g VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^h MCLEAN HOSPITAL   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^k University of Texas Medical Branch School of Medicine   (United States)

^l Department of Psychiatry ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

LITHIUM; PLACEBO; VALPROATE SEMISODIUM;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MANIC DEPRESSIVE PSYCHOSIS; MULTICENTER STUDY; OUTCOMES RESEARCH; POLYURIA; RECURRENT DISEASE; TINNITUS;

EID: 0034013393     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.57.5.481     Document Type: Article

References (36)

1. Baastrup PC, Poulsen JC, Schou M, Thomsen K, Amdisen A. Prophylactic lithium: double-blind discontinuation in manic-depressive and recurrent-depressive disorders. Lancet. 1970;2:326-330.
2. Coppen A, Noguira R, Bailey J, Burns BH, Swani MS, Hare EH, Gardner R, Maggs R. Prophylactic lithium in affective disorders. Lancet. 1971;2:275-279.
3. Cundall RL, Brooks PW, Murray LG. A controlled evaluation of lithium prophylaxis in affective disorders. Psychol Med. 1972;2:308-311.
4. Melia PI. Prophylactic lithium: a double-blind trial in recurrent affective disorders. Br J Psychiatry. 1970;116:621-624.
5. Prier RF, Caffey EM Jr, Klett CJ, Prophylactic efficacy of lithium carbonate in manic-depressive illness: report of the Veterans Administration and National Institute of Mental Health collaborative study group. Arch Gen Psychiatry. 1973; 28:337-341.
6. Harrow M, Goldberg JF, Grossman LS, Meltzer HY. Outcome in manic disorders: a naturalistic follow-up study. Arch Gen Psychiatry. 1990;47:665-671.
7. O'Connell RA, Mayo JA, Flatow L, Cuthbertson B. O'Brien BE. Outcome of bipolar disorder on long-term treatment with lithium. Br J Psychiatry. 1991;159:123-129.
8. Tohen M, Waternaux CM, Tsuang MT. Outcome in mania: a 4-year prospective follow-up of 75 patients utilizing survival analysis. Arch Gen Psychiatry. 1990; 47:1106-1111.
9. Coryell W, Winokur G, Solomon D, Shea T, Leon A, Keller M, Lithium and recurrence in a long-term follow-up of bipolar affective disorder. Psychol Med. 1997; 27:281-289.
10. Vestergaard P. Licht RW, Brodersen A, Rasmussen NA, Christensen H, Arngrim T, Gronvall B, Kristensen E, Poulstrup I. Outcome of lithium prophylaxis: a prospective follow-up of affective disorder patients assigned to high and low serum lithium levels. Acta Psychiatr Scand. 1998;98:310-315.
11. Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, Oilsaver SC, Davis JM, Rush AJ, Small JG, Garza-Trevino ES, Risch SC, Goodnick PJ, Morris DD, for the Depakoke Mania Study Group. Efficacy of divalproex vs litnium and placebo in the treatment of mania. JAMA 1994;271:918-924.
12. Pope HG Jr, McElroy SL, Keck PE Jr, Hudson JI. Valproate in the treatment of acute mania: a placebo-controlled study. Arch Gen Psychiatry. 1991;48:62-68.
13. Lambert PA, Venaud G. Comparative study of valpromide versus lithium in the treatmerrt of affective disorders. Nervure. 1992:5:57-65.
14. Calabrese JR, Delucchi GA. Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder. Am J Psychiatry. 1990;147:431-434.
15. McElroy SL, Keck PE Jr, Pope HG Jr. Sodium valproate: its use in primary psychiatric disorders. J Clin Psychopharmacol. 1987;7:16-24.
16. Spitzer RL, Williams JBW, Gibbons M, First MB. Structured Clinical Interview for the DSM-III-R. Washington, DC: American Psychiatric Press Inc: 1990.
17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Revised Third Edition. Washington, DC: American Psychiatric Association; 1987.
18. Secunda S, Katz MM, Swann A, Koslow SH, Maas JW, Chuang S, Croughan J. Mania: diagnosis, state measurement and prediction of treatment response. J Affect Disord 1985;8:113-121.
19. Endicott J, Spitzer RL. A diagnostic interview: the schedule of affective disorders and schizophrenia. Arch Gen Psychiatry. 1978;35:837-844.
20. Swann AC, Bowden CL, Morris D. Calabrese JR, Petty F, Small J, Dilsaver SC, Davis JM. Depression during mania: treatment response to lithium or divalproex. Arch Gen Psychiatry. 1997;54:37-42.
21. Bowden CL, Calabrese JR, Wallin BA, Swann AC, McElroy SL, Risch SC, Hirschfeld MA. Who enters therapeutic trials: illness characteristics of patients in clinical drug studies of mania. Psychopharmacol Bull. 1995;31:103-109.
22. Bowden CL, Swann AC, Calabrese JR, McElroy SL, Morris D, Petty FL, Hirschfeld RM, Gyulai L. Maintenance clinical trials in bipolar disorder: design implications of the divalproex-lithium-placebo study. Psychopharmacol Bull. 1997; 33:693-699.
23. SAS/STAT User's Guide, Version 6. 4th ed Cary, NC: SAS Institute Inc; 1989.
24. Lawless JF. Statistical Models and Methods for Lifetime Data. New York, NY: John Wiley & Sons; 1982:423.
25. COSTART: Coding Symbols for Thesaurus of Adverse Reaction Terms. 3rd ed. Rockville. Md: Division of Drug and Biological Product Experience, Center for Drugs and Biologics, Food and Drug Administration, Dept of Health and Human Services; 1989.
26. Maj M, Pirozzi R, Kemali D. Long-term outcome of lithium prophylaxis in patients initially classified as complete responders. Psychopharmacology. 1989; 98:535-538.
27. Goldberg JF, Harrow M, Grossman LS. Course and outcome in bipolar affective disorder. Am J Psychiatry. 1995;152:379-384.
28. Suppes T, Baldessarini RJ, Faedda GL, Tohen M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry. 1991;48:1082-1088.
29. Faedda GL, Tondo L, Baldessarini RJ, Suppes T, Tohen M. Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar disorders. Arch Gen Psychiatry. 1991;50:448-455.
30. Baldessarini RJ, Tondo L, Floris G, Rudas N. Reduced morbidity after gradually discontinuing lithium in bipolar I and II disorders: a replication study. Am J Psychiatry. 1997;154:551-553.
31. Uhlenhuth EH, Matuzas W, Warner TD, Thompson PM Growing placebo response rate: the problem in recent therapeutic trials? Psychopharmacol Bull. 1997; 33:31-39.
32. Fisher S, Lipman RS, Uhlenhuth EH, Rickels K, Park LC. Drug effects and initial severity of symptomatology. Psychopharmacologia. 1965;7:57-60.
33. Benjamin LS. Statistical treatment of the Law of Initial Values (LIV) in autonomic research: a review and recommendation. Psychosom Med. 1963;25:556-566.
34. Hullin RP, McDonald R, Allsopp MN. Further report on prophylactic lithium in recurrent affective disorders. Br J Psychiatry. 1975;126:281-284.
35. Fieve RR, Kumbaraci T, Dunner DL. Lithium prophylaxis of depression in bipolar I, bipolar II, and unipolar patients. Am J Psychiatry. 1976;133:925-929.
36. Greil W, Ludwig-Mayerhofer W, Erazo N, Schöchlin C, Schmidt S, Engel RR, Czernik A, Giedke H, Müller-Oerlinghausen B, Osterheider M, Rudolf GA, Sauer H, Tegeler J, Wetterling T. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders: a randomised study. J Affect Disord 1997;43:151-161.